Product Description
Omarigliptin(MK-3102) is a DPP-4 inhibitor being developed as a once-weekly treatment for T2D. Its regulatory filing with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is supported by results from a Phase 3 study of the drug conducted in Japan. The clinical development program for omarigliptin also includes several other late-stage trials that enrolled an estimated 7,500 patients with T2D. Results show that omarigliptin demonstrated comparable efficacy to sitagliptin.
| Payment Terms: | TT/Western Union |
| |
Product Image
Img 1
Send Inquiry to this Member
Related Products of this Company
This member assumes full responsibility for the content of this listing. DIYTrade accepts no responsibility whatsoever in respect of such content.
To report fraudulent or illegal content, please
click here.
China Suppliers Quick Searching:
,
